Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00447083
Other study ID # II-CDR-Fibromyalgia
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2005
Est. completion date September 2008

Study information

Verified date October 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

- To establish whether ultraviolet light exposure acutely reduces perceptions of pain in patients with fibromyalgia.

- To establish whether a series of UV light exposures has a cumulative effect on fibromyalgia pain.


Description:

Fibromyalgia is a common chronic disorder characterized by widespread pain and fatigue. It occurs primarily in women, especially women of childbearing age. The effectiveness of treatment for this disorder is limited, and alternative medical treatments are commonly used.

Ultraviolet (UV) light exposure gives a sense of relaxation. It is unknown whether UV exposure has any effect on pain, particularly in patients with fibromyalgia. Through studies performed with RO3 funding from the National Institute of Drug Abuse (NIDA), we demonstrated that in frequent tanners, appearance is less important than UV-induced relaxation in motivating tanning behavior. Moreover, we determined that UV light has reinforcing properties apart from any psychosocial benefits of having a tan. One subject in our study reported low back pain relief from the UV exposure condition.

This is a two-year proposal that is the beginning of a long-term plan to assess whether indoor tanning ultraviolet light exposure has a therapeutic effect for patients with chronic pain. To this end, we will determine the effect of UV light on fibromyalgia pain in a controlled, double blind clinical trial of UV exposure. This approach is carefully designed to separate the effects of UV exposure on pain from potential confounds associated with the tanning procedure, including any perceived benefits of having a tan. The results of this study will increase our understanding of the specific influence of UV light on persistence in tanning behavior.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers No
Gender All
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria:

- Fibromyalgia patients who meet the fibromyalgia criteria, and who have been diagnosed with fibromyalgia by a board certified rheumatologist. The fibromyalgia criteria {as defined by the American College of Rheumatology (ACR)} require the patient to have: at least 3 months of widespread pain defined as: bilateral; above and below the waist, including axial skeletal pain; and pain to palpation with 4kg of pressure at a minimum of 11 out of 18 predefined tender points.

- Ideally, patients should not be taking medication for treatment of fibromyalgia, and they should not be taking psychoactive medications on an as needed basis for treatment of fibromyalgia. However, if patients are taking psychoactive or other medications for the treatment of fibromyalgia, then they should be on a stable dose, defined as no change in dosage in the 4 weeks prior to study enrollment.

- Patients must agree to not partake in tanning bed UV exposure during the study.

Exclusion Criteria:

- Fitzpatrick skin type 1 ("never tan, always burn")

- Past or present skin cancer

- Current use of photosensitizing drugs (current use of photosensitizing drugs will be evaluated via a patient questionnaire at time of patient enrollment - see Appendix 1),, psychoactive medications (not a stable dose, defined as no change in dosage in the 4 weeks prior to study enrollment), or illicit drugs

- Pregnant, planning to become pregnant, or breast feeding

- Significant visual discrimination of UV versus non-UV conditions

- Greater than 6 indoor tanning sessions over the past year

- Concurrent photosensitive disease, positive antinuclear antibody test, positive anti-Smith antibody test, or positive anti-dsDNA test.

Study Design


Intervention

Device:
UVB
UVB exposure by a tanning bed
Procedure:
Non-UVB
Non-UVB exposure by a tanning bed

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Relief Success Rates (Phase I) Percentage of exposures that showed pain relief (2 point improvement in Likert scale) in the 11 point Likert scale. 2 weeks
Primary Pain Score- Likert Scale(Phase II) Pain will be assessed on an 11-point pain scale where 0=no pain and 10=worst possible pain. A 30% improvement in reported pain will be considered a treatment "success. 6 weeks
Secondary Post-treatment Pain Scores- Likert Scale (Phase I) As a secondary outcome, the post-treatment pain scores between the UV and non-UV exposures given on the first day the dose is given will be compared. Pain will be assessed on an 11-point pain Likert scale where 0=no pain and 10=worst possible pain 2 weeks
Secondary Pain Scores of the UV and Non-UV Exposure (Phase II) The pain scores were assessed using a Likert Scale. Pain will be assessed on an 11-point pain Likert scale where 0=no pain and 10=worst possible pain. 4 weeks post-treatment
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05933486 - Efficacy and Safety of Tongluo-Kaibi Tablet in Patients With Fibromyalgia Syndrome Phase 4
Completed NCT01642810 - Online Acceptance-based Behavioural Treatment for Fibromyalgia Phase 3
Completed NCT00757731 - FMS European Long-Term Study Phase 3
Completed NCT00757679 - Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran Phase 2
Completed NCT01968772 - Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia N/A
Completed NCT00401830 - Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Phase 2
Completed NCT04517929 - Effectiveness of Group Psychotherapy in Patients With Fibromyalgia Syndrome N/A
Completed NCT06285045 - Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression N/A
Completed NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT02800720 - Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome N/A
Not yet recruiting NCT01465477 - Influenza Vaccination in Fibromyalgia Patients N/A
Completed NCT00528710 - Efficacy of S-Adenosylmethionine in Fibromyalgia Phase 2
Not yet recruiting NCT06147882 - The Effect of Positive Psychotherapy Based Psychoeducation on Pain Perception With Fibromyalgia Syndrome N/A
Completed NCT05381012 - Fibromyalgia Syndrome on Patients With Chronic Migraine N/A
Completed NCT00464737 - The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Phase 2
Completed NCT04426864 - Efficacy of Different Types of Exercises in Women With Fibromyalgia Syndrome. N/A
Completed NCT02881411 - Self Soft Tissue Therapy for Fibromyalgia Syndrome N/A
Completed NCT01389336 - Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone N/A
Not yet recruiting NCT01147263 - Palpitations and Tachycardia in Fibromyalgia Syndrome N/A
Completed NCT00222274 - HRV Biofeedback in Fibromyalgia N/A